Targeted Genetics Sells AAV, Manufacturing Tech to Genzyme for $7M

As part of the deal, which is expected to give Targeted Genetics enough cash to continue operations through 2010, the firm licensed back the technology and IP for certain drug-development efforts, including its RNAi-based Huntington’s disease program.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.